

ANNEX 2

---

# Country profiles



# Afghanistan

## HIGH TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	13 (8.4–16)	42 (27–53)
Mortality (HIV+TB only)	0.082 (0.065–0.1)	0.27 (0.21–0.33)
Prevalence (includes HIV+TB)	100 (54–170)	340 (178–554)
Incidence (includes HIV+TB)	58 (51–65)	189 (167–212)
Incidence (HIV+TB only)	0.2 (0.17–0.22)	0.64 (0.57–0.72)
Case detection, all forms (%)	53 (47–60)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	3.7 (2.5–4.9)	20 (13–27)
MDR-TB cases among notified pulmonary TB cases	820 (560–1 100)	460 (300–610)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	14 277	1 154
Pulmonary, clinically diagnosed	8 020	
Extrapulmonary	7 056	

<b>Total new and relapse</b>	<b>30 507</b>
Previously treated, excluding relapses	1 115
<b>Total cases notified</b>	<b>31 622</b>

Among 30 507 new and relapse cases:

3 454 (11%) cases aged under 15 years; male:female ratio: 0.7

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	7 (<1%)	38 (2%)	45
Laboratory-confirmed RR-/MDR-TB cases			73
Patients started on MDR-TB treatment			49

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	8 247	(26)
HIV-positive TB patients	9	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB	100	
HIV-positive people provided with IPT	12	

### Treatment success rate (%)

New and relapse cases registered in 2012	88
Previously treated cases, excluding relapse, registered in 2012	65
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	29
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	2.2
Culture (per 5 million population)	0.5
Drug susceptibility testing (per 5 million population)	0
Sites performing Xpert MTB/RIF	1
Is second-line drug susceptibility testing available?	Yes, outside country

### Financing TB control 2014







National TB programme budget (US\$ millions)	9.5
% Funded domestically	8%
% Funded internationally	57%
% Unfunded	35%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **31 million**



# Bangladesh

## HIGH TB BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	80 (51–110)	51 (33–69)
Mortality (HIV+TB only)	0.16 (0.1–0.24)	0.1 (0.07–0.15)
Prevalence (includes HIV+TB)	630 (330–1 000)	402 (210–656)
Incidence (includes HIV+TB)	350 (310–400)	224 (199–253)
Incidence (HIV+TB only)	0.41 (0.18–0.46)	0.26 (0.12–0.3)
Case detection, all forms (%)	53 (47–59)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.7–2.5)	29 (24–34)
MDR-TB cases among notified pulmonary TB cases	2 100 (1 000–3 700)	2 600 (2 200–3 200)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	105 539	2 869
Pulmonary, clinically diagnosed	42 394	0
Extrapulmonary	33 704	0

**Total new and relapse** 184 506

Previously treated, excluding relapses 6 385

**Total cases notified** 190 891

Among 181 637 new cases:

5 051 (3%) cases aged under 15 years; male:female ratio: 1.5

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	446 (<1%)	4 611 (50%)	11 219
Laboratory-confirmed RR-/MDR-TB cases			1 024
Patients started on MDR-TB treatment			684

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	2 067	(1)
HIV-positive TB patients	68	(3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	61	(90)
HIV-positive TB patients on antiretroviral therapy (ART)	68	(100)
HIV-positive people screened for TB	607	
HIV-positive people provided with IPT	0	

### Treatment success rate (%)

New and relapse cases registered in 2012	92
Previously treated cases, excluding relapse, registered in 2012	82
HIV-positive TB cases, all types, registered in 2012	81
RR-/MDR-TB cases started on second-line treatment in 2011	68
XDR-TB cases started on second-line treatment in 2011	100

### Laboratories 2013

Smear (per 100 000 population)	0.7
Culture (per 5 million population)	<0.1
Drug susceptibility testing (per 5 million population)	<0.1
Sites performing Xpert MTB/RIF	26
Is second-line drug susceptibility testing available?	Yes, in and outside country

### Financing TB control 2014







National TB programme budget (US\$ millions)	57
% Funded domestically	5%
% Funded internationally	33%
% Unfunded	62%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals. Estimates of TB disease burden have not been approved by the national TB programme in Bangladesh and a joint reassessment will be undertaken following the completion of the prevalence survey planned for 2015.

<sup>b</sup> Includes cases with unknown previous TB treatment history

Population 2013 **157 million**



# Brazil

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	4.4 (2.5–6.8)	2.2 (1.3–3.4)
Mortality (HIV+TB only)	2.1 (1.5–2.7)	1 (0.77–1.4)
Prevalence (includes HIV+TB)	110 (54–200)	57 (27–99)
Incidence (includes HIV+TB)	93 (83–110)	46 (41–52)
Incidence (HIV+TB only)	13 (13–13)	6.5 (6.5–6.6)
Case detection, all forms (%)	82 (72–92)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (1–1.8)	7.5 (5.7–9.9)
MDR-TB cases among notified pulmonary TB cases	840 (600–1 100)	940 (710–1 200)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	41 885	3 613
Pulmonary, clinically diagnosed	18 303	1 604
Extrapulmonary	10 148	467

<b>Total new and relapse</b>	<b>76 020</b>
Previously treated, excluding relapses	7 290
<b>Total cases notified</b>	<b>83 310</b>

Among 76 020 new and relapse cases:

2 647 (3%) cases aged under 15 years; male:female ratio: 2.0

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	670 (2%)	217 (2%)	895
Laboratory-confirmed RR-/MDR-TB cases			706
Patients started on MDR-TB treatment			717

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	54 213	(65)
HIV-positive TB patients	9 340	(17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	72
Previously treated cases, excluding relapse, registered in 2012	36
HIV-positive TB cases, all types, registered in 2012	48
RR-/MDR-TB cases started on second-line treatment in 2011	56
XDR-TB cases started on second-line treatment in 2011	21

### Laboratories 2013

Smear (per 100 000 population)	1.5
Culture (per 5 million population)	8.6
Drug susceptibility testing (per 5 million population)	1.0
Sites performing Xpert MTB/RIF	0
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	79
% Funded domestically	87%
% Funded internationally	2%
% Unfunded	12%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **200 million**



# Cambodia

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	10 (6.3–14)	66 (42–92)
Mortality (HIV+TB only)	0.59 (0.45–0.76)	3.9 (3–5)
Prevalence (includes HIV+TB)	110 (91–130)	715 (604–834)
Incidence (includes HIV+TB)	61 (55–67)	400 (366–444)
Incidence (HIV+TB only)	2.3 (2.1–2.6)	15 (14–17)
Case detection, all forms (%)	62 (56–68)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.7–2.5)	11 (4–22)
MDR-TB cases among notified pulmonary TB cases	320 (160–580)	180 (68–370)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	14 082	389
Pulmonary, clinically diagnosed	9 069	0
Extrapulmonary	14 203	0

<b>Total new and relapse</b>	<b>37 743</b>
Previously treated, excluding relapses	1 312
<b>Total cases notified</b>	<b>39 055</b>

Among 14 083 new cases:

64 (<1%) cases aged under 15 years; male:female ratio: 1.2

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	338 (2%)	1 255 (74%)	1 593
Laboratory-confirmed RR-/MDR-TB cases			121
Patients started on MDR-TB treatment			121

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	32 176	(82)
HIV-positive TB patients	1 241	(4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	1 107	(89)
HIV-positive TB patients on antiretroviral therapy (ART)	1 100	(89)
HIV-positive people screened for TB	1 241	
HIV-positive people provided with IPT	1 343	

### Treatment success rate (%)

New and relapse cases registered in 2012	94
Previously treated cases, excluding relapse, registered in 2012	88
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	86
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.4
Culture (per 5 million population)	1.3
Drug susceptibility testing (per 5 million population)	0.3
Sites performing Xpert MTB/RIF	10
Is second-line drug susceptibility testing available?	No

### Financing TB control 2014







National TB programme budget (US\$ millions)	31
% Funded domestically	4%
% Funded internationally	32%
% Unfunded	64%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **15 million**



# China

## HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	41 (40–43)	3 (2.9–3.1)
Mortality (HIV+TB only)	0.67 (0.23–1.3)	0.05 (0.02–0.1)
Prevalence (includes HIV+TB)	1 300 (1 100–1 500)	94 (82–107)
Incidence (includes HIV+TB)	980 (910–1 100)	70 (66–77)
Incidence (HIV+TB only)	4.5 (4.3–9.9)	0.33 (0.31–0.72)
Case detection, all forms (%)	87 (79–93)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	5.7 (4.5–7)	26 (22–30)
MDR-TB cases among notified pulmonary TB cases	45 000 (35 000–55 000)	9 200 (7 800–11 000)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	275 915	28 025
Pulmonary, clinically diagnosed	512 469	
Extrapulmonary	30 767	

**Total new and relapse** **847 176**

Previously treated, excluding relapses 8 065

**Total cases notified** **855 241**

Among 847 176 new and relapse cases:

4 830 (<1%) cases aged under 15 years; male:female ratio: 2.2

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	30 156 (11%)	11 656 (32%)	41 812
Laboratory-confirmed RR-/MDR-TB cases			4 183
Patients started on MDR-TB treatment			2 184

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	329 415	(39)
HIV-positive TB patients	4 649	(1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	3 127	(67)
HIV-positive people screened for TB	358 345	
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	95
Previously treated cases, excluding relapse, registered in 2012	90
HIV-positive TB cases, all types, registered in 2012	47
RR-/MDR-TB cases started on second-line treatment in 2011	50
XDR-TB cases started on second-line treatment in 2011	25

### Laboratories 2013

Smear (per 100 000 population)	0.2
Culture (per 5 million population)	4.6
Drug susceptibility testing (per 5 million population)	0.9
Sites performing Xpert MTB/RIF	160
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	347
% Funded domestically	78%
% Funded internationally	3%
% Unfunded	19%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **1 386 million**



# Democratic Republic of the Congo

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	46 (22–53)	68 (33–78)
Mortality (HIV+TB only)	6.4 (0.17–24)	9.5 (0.25–35)
Prevalence (includes HIV+TB)	370 (190–610)	549 (285–898)
Incidence (includes HIV+TB)	220 (200–240)	326 (297–356)
Incidence (HIV+TB only)	16 (9.8–75)	24 (14–111)
Case detection, all forms (%)	51 (47–56)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.6 (0.01–5.5)	13 (0.2–28)
MDR-TB cases among notified pulmonary TB cases	2 200 (9–4 700)	900 (14–2 000)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	71 526	3 981
Pulmonary, clinically diagnosed	13 887	1 943
Extrapulmonary	20 297	805

**Total new and relapse** 112 439

Previously treated, excluding relapses 1 164

**Total cases notified** 113 603

Among 71 526 new cases:

3 086 (4%) cases aged under 15 years; male:female ratio: 1.3

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	344 (<1%)	1 070 (14%)	1 426
Laboratory-confirmed RR-/MDR-TB cases			272
Patients started on MDR-TB treatment			147

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	49 816	(44)
HIV-positive TB patients	6 984	(14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	4 866	(70)
HIV-positive TB patients on antiretroviral therapy (ART)	3 371	(48)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate (%)

New cases registered in 2012	88
Previously treated cases registered in 2012	74
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	59
XDR-TB cases started on second-line treatment in 2011	

## Laboratories 2013

Smear (per 100 000 population)	2.3
Culture (per 5 million population)	0.1
Drug susceptibility testing (per 5 million population)	<0.1
Sites performing Xpert MTB/RIF	26
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014






National TB programme budget (US\$ millions)	66
% Funded domestically	3%
% Funded internationally	21%
% Unfunded	75%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **68 million**





# Ethiopia

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	30 (16–47)	32 (17–50)
Mortality (HIV+TB only)	5.6 (3.6–8)	5.9 (3.8–8.5)
Prevalence (includes HIV+TB)	200 (160–240)	211 (170–257)
Incidence (includes HIV+TB)	210 (180–260)	224 (188–276)
Incidence (HIV+TB only)	22 (19–32)	24 (21–33)
Case detection, all forms (%)	62 (51–74)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.6 (0.9–2.8)	12 (5.6–21)
MDR-TB cases among notified pulmonary TB cases	1 400 (800–2 500)	

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	43 860	
Pulmonary, clinically diagnosed	45 464	
Extrapulmonary	42 353	

**Total new and relapse** 131 677

Previously treated, excluding relapses

**Total cases notified** 131 677

Among 131 677 new cases:

21 317 (16%) cases aged under 15 years; male:female ratio: 1.2

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	212 (<1%)	1 095	3 071
Laboratory-confirmed RR-/MDR-TB cases			558
Patients started on MDR-TB treatment			413

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	93 356	(71)
HIV-positive TB patients	10 374	(11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	7 055	(68)
HIV-positive people screened for TB	324 674	
HIV-positive people provided with IPT	15 424	

## Treatment success rate (%)

New cases registered in 2012	91
Previously treated cases registered in 2012	43
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	72
XDR-TB cases started on second-line treatment in 2011	

## Laboratories 2013

Smear (per 100 000 population)	2.2
Culture (per 5 million population)	0.4
Drug susceptibility testing (per 5 million population)	0.4
Sites performing Xpert MTB/RIF	23
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014







National TB programme budget (US\$ millions)	94
% Funded domestically	7%
% Funded internationally	30%
% Unfunded	63%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals. Estimates of TB disease burden for Ethiopia are provisional pending a joint review by WHO and the MOH in early 2015.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **94 million**



# India

## HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	240 (150–350)	19 (12–28)
Mortality (HIV+TB only)	38 (31–44)	3 (2.5–3.5)
Prevalence (includes HIV+TB)	2 600 (1 800–3 700)	211 (143–294)
Incidence (includes HIV+TB)	2 100 (2 000–2 300)	171 (162–184)
Incidence (HIV+TB only)	120 (100–140)	9.7 (8.3–11)
Case detection, all forms (%)	58 (54–61)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.2 (1.9–2.6)	15 (11–19)
MDR-TB cases among notified pulmonary TB cases	20 000 (17 000–24 000)	41 000 (30 000–52 000)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	621 762	102 660
Pulmonary, clinically diagnosed	292 926	
Extrapulmonary	226 557	

**Total new and relapse** **1 243 905**

Previously treated, excluding relapses 171 712

**Total cases notified** **1 415 617**

Among 1 243 905 new and relapse cases:

64 726 (5%) cases aged under 15 years

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			248 341
Laboratory-confirmed RR-/MDR-TB cases			35 385
Patients started on MDR-TB treatment			20 763

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	887 903	(63)
HIV-positive TB patients	44 027	(5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	41 827	(95)
HIV-positive TB patients on antiretroviral therapy (ART)	38 754	(88)
HIV-positive people screened for TB	1 063 644	
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	88
Previously treated cases, excluding relapse, registered in 2012	74
HIV-positive TB cases, all types, registered in 2012	77
RR-/MDR-TB cases started on second-line treatment in 2011	50
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.0
Culture (per 5 million population)	0.2
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	54
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	252
% Funded domestically	66%
% Funded internationally	34%
% Unfunded	0%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals. Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India, and should therefore be considered provisional.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **1 252 million**



# Indonesia

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	64 (36–93)	25 (14–37)
Mortality (HIV+TB only)	3.9 (2.2–6.2)	1.6 (0.87–2.5)
Prevalence (includes HIV+TB)	680 (340–1 100)	272 (138–450)
Incidence (includes HIV+TB)	460 (410–520)	183 (164–207)
Incidence (HIV+TB only)	15 (8.7–20)	5.8 (3.5–7.8)
Case detection, all forms (%)	71 (63–80)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.9 (1.4–2.5)	12 (8.1–17)
MDR-TB cases among notified pulmonary TB cases	5 700 (4 200–7 500)	1 100 (770–1 600)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	196 310	6 406
Pulmonary, clinically diagnosed	103 888	1 558
Extrapulmonary	17 420	

**Total new and relapse** 325 582

Previously treated, excluding relapses 1 521

**Total cases notified** 327 103

Among 325 582 new and relapse cases:

26 054 (8%) cases aged under 15 years; male:female ratio: 1.4

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	53 (<1%)	3 740 (39%)	3 838
Laboratory-confirmed RR-/MDR-TB cases			912
Patients started on MDR-TB treatment			809

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	7 631	(2)
HIV-positive TB patients	1 599	(21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	477	(30)
HIV-positive TB patients on antiretroviral therapy (ART)	332	(21)
HIV-positive people screened for TB	22 190	
HIV-positive people provided with IPT		

## Treatment success rate (%)

New and relapse cases registered in 2012	86
Previously treated cases, excluding relapse, registered in 2012	71
HIV-positive TB cases, all types, registered in 2012	49
RR-/MDR-TB cases started on second-line treatment in 2011	60
XDR-TB cases started on second-line treatment in 2011	50

## Laboratories 2013

Smear (per 100 000 population)	2.2
Culture (per 5 million population)	0.4
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	23
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014







National TB programme budget (US\$ millions)	127
% Funded domestically	13%
% Funded internationally	30%
% Unfunded	57%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **250 million**



# Kenya

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	9.1 (5.5–12)	20 (12–27)
Mortality (HIV+TB only)	9.5 (7.5–12)	21 (17–27)
Prevalence (includes HIV+TB)	130 (69–200)	283 (156–447)
Incidence (includes HIV+TB)	120 (120–120)	268 (261–275)
Incidence (HIV+TB only)	48 (47–50)	109 (105–112)
Case detection, all forms (%)	75 (74–77)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.6 (0.01–5.5)	13 (0.2–28)
MDR-TB cases among notified pulmonary TB cases	1 700 (7–3 700)	1 100 (17–2 300)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	34 686	4 632
Pulmonary, clinically diagnosed	32 153	3 847
Extrapulmonary	14 478	0

**Total new and relapse** 89 796

Previously treated, excluding relapses

**Total cases notified** 89 796

Among 74 335 new cases:

4 383 (6%) cases aged under 15 years; male:female ratio: 1.4

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	127 (<1%)	1 846 (22%)	2 116
Laboratory-confirmed RR-/MDR-TB cases			160
Patients started on MDR-TB treatment			290

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	84 178	(94)
HIV-positive TB patients	31 650	(38)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	31 380	(99)
HIV-positive TB patients on antiretroviral therapy (ART)	26 431	(84)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	86
Previously treated cases, excluding relapse, registered in 2012	78
HIV-positive TB cases, all types, registered in 2012	83
RR-/MDR-TB cases started on second-line treatment in 2011	70
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	4.2
Culture (per 5 million population)	0.8
Drug susceptibility testing (per 5 million population)	0.7
Sites performing Xpert MTB/RIF	21
Is second-line drug susceptibility testing available?	No

### Financing TB control 2014







National TB programme budget (US\$ millions)	57
% Funded domestically	23%
% Funded internationally	17%
% Unfunded	60%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **44 million**



# Mozambique

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	18 (9.4–26)	69 (36–101)
Mortality (HIV+TB only)	38 (27–51)	148 (105–198)
Prevalence (includes HIV+TB)	140 (78–230)	559 (303–893)
Incidence (includes HIV+TB)	140 (110–180)	552 (442–680)
Incidence (HIV+TB only)	81 (64–100)	312 (248–388)
Case detection, all forms (%)	37 (30–47)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	3.5 (2.2–4.8)	11 (0–25)
MDR-TB cases among notified pulmonary TB cases	1 500 (950–2 100)	830 (0–1 900)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	23 115	2 081
Pulmonary, clinically diagnosed	20 131	2 422
Extrapulmonary	5 523	

### Total new and relapse

53 272

### Previously treated, excluding relapses

2 948

### Total cases notified

56 220

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	634 (3%)	653 (9%)	1 287
Laboratory-confirmed RR-/MDR-TB cases			444
Patients started on MDR-TB treatment			313

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	51 172	(91)
HIV-positive TB patients	28 585	(56)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	27 624	(97)
HIV-positive TB patients on antiretroviral therapy (ART)	20 449	(72)
HIV-positive people screened for TB		
HIV-positive people provided with IPT	48 188	

### Treatment success rate (%)

New cases registered in 2012	87
Previously treated cases registered in 2012	
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	31
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.3
Culture (per 5 million population)	0.6
Drug susceptibility testing (per 5 million population)	0.4
Sites performing Xpert MTB/RIF	14
Is second-line drug susceptibility testing available?	Yes, outside country

### Financing TB control 2014







National TB programme budget (US\$ millions)	19
% Funded domestically	
% Funded internationally	22%
% Unfunded	78%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **26 million**



# Myanmar

## HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	26 (16–38)	49 (29–71)
Mortality (HIV+TB only)	4.3 (3.3–5.3)	8 (6.3–9.9)
Prevalence (includes HIV+TB)	250 (190–320)	473 (364–595)
Incidence (includes HIV+TB)	200 (180–220)	373 (340–413)
Incidence (HIV+TB only)	17 (16–18)	33 (30–34)
Case detection, all forms (%)	68 (61–74)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	5 (3.1–6.8)	27 (15–39)
MDR-TB cases among notified pulmonary TB cases	5 700 (3 500–7 700)	3 300 (1 800–4 800)

### TB case notifications 2013<sup>b</sup>

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	42 595	4 854
Pulmonary, clinically diagnosed	70 519	
Extrapulmonary	16 887	

### Total new and relapse

Previously treated, excluding relapses 7 307

### Total cases notified

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>c</sup>
Cases tested for RR-/MDR-TB	5 527 (13%)	8 551 (70%)	14 246
Laboratory-confirmed RR-/MDR-TB cases			1 984
Patients started on MDR-TB treatment			667

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	16 882	(12)
HIV-positive TB patients	5 413	(32)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	4 826	(89)
HIV-positive TB patients on antiretroviral therapy (ART)	3 987	(74)
HIV-positive people screened for TB	45 337	
HIV-positive people provided with IPT	468	

### Treatment success rate (%)

New cases registered in 2012	89
Previously treated cases registered in 2012	70
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	71
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	0.9
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	24
Is second-line drug susceptibility testing available?	Yes, outside country

### Financing TB control 2014

National TB programme budget (US\$ millions)	36
% Funded domestically	15%
% Funded internationally	49%
% Unfunded	35%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Case notifications were updated after TB burden estimates had already been produced.

<sup>c</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **53 million**



# Nigeria

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	160 (68–270)	94 (39–156)
Mortality (HIV+TB only)	85 (47–140)	49 (27–78)
Prevalence (includes HIV+TB)	570 (430–730)	326 (246–418)
Incidence (includes HIV+TB)	590 (340–880)	338 (194–506)
Incidence (HIV+TB only)	140 (81–220)	81 (47–124)
Case detection, all forms (%)	16 (11–28)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.9 (2.1–4)	14 (10–19)
MDR-TB cases among notified pulmonary TB cases	2 500 (1 800–3 500)	1 200 (860–1 600)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	52 811	2 828
Pulmonary, clinically diagnosed	33 873	
Extrapulmonary	5 313	

**Total new and relapse** 94 825

Previously treated, excluding relapses 5 576

**Total cases notified** 100 401

Among 100 401 new and relapse cases:

5 776 (6%) cases aged under 15 years; male:female ratio: 1.5

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			10 410
Laboratory-confirmed RR-/MDR-TB cases			669
Patients started on MDR-TB treatment			426

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	88 317	(88)
HIV-positive TB patients	19 423	(22)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	16 948	(87)
HIV-positive TB patients on antiretroviral therapy (ART)	12 923	(67)
HIV-positive people screened for TB	435 216	
HIV-positive people provided with IPT	7 973	

## Treatment success rate (%)

New cases registered in 2012	86
Previously treated cases registered in 2012	83
HIV-positive TB cases, all types, registered in 2012	79
RR-/MDR-TB cases started on second-line treatment in 2011	63
XDR-TB cases started on second-line treatment in 2011	

## Laboratories 2013

Smear (per 100 000 population)	0.9
Culture (per 5 million population)	0.1
Drug susceptibility testing (per 5 million population)	<0.1
Sites performing Xpert MTB/RIF	49
Is second-line drug susceptibility testing available?	Yes, outside country

## Financing TB control 2014







National TB programme budget (US\$ millions)	139
% Funded domestically	9%
% Funded internationally	38%
% Unfunded	53%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **174 million**





# Pakistan

## HIGH TB BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	100 (45–170)	56 (25–92)
Mortality (HIV+TB only)	0.97 (0.52–1.6)	0.53 (0.28–0.86)
Prevalence (includes HIV+TB)	620 (520–740)	342 (284–406)
Incidence (includes HIV+TB)	500 (370–650)	275 (205–357)
Incidence (HIV+TB only)	2.6 (1.2–3.4)	1.4 (0.64–1.9)
Case detection, all forms (%)	58 (44–78)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	4.3 (2.8–5.7)	19 (14–25)
MDR-TB cases among notified pulmonary TB cases	9 900 (6 400–13 000)	3 100 (2 200–4 000)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	111 682	6 303
Pulmonary, clinically diagnosed	118 279	0
Extrapulmonary	52 646	0

<b>Total new and relapse</b>	<b>288 910</b>
Previously treated, excluding relapses	9 536
<b>Total cases notified</b>	<b>298 446</b>

Among 282 607 new cases:

28 113 (10%) cases aged under 15 years; male:female ratio: 1.0

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	5 161 (5%)	3 510 (22%)	12 777
Laboratory-confirmed RR-/MDR-TB cases			2 596
Patients started on MDR-TB treatment			1 495

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	8 306	(3)
HIV-positive TB patients	36	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

### Treatment success rate (%)

New cases registered in 2012	91
Previously treated cases registered in 2012	81
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	70
XDR-TB cases started on second-line treatment in 2011	43

### Laboratories 2013

Smear (per 100 000 population)	0.8
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	32
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	114
% Funded domestically	
% Funded internationally	30%
% Unfunded	70%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **182 million**





# Philippines

## HIGH TB BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	27 (25–29)	27 (25–29)
Mortality (HIV+TB only)	0.058 (0.042–0.077)	0.06 (0.04–0.08)
Prevalence (includes HIV+TB)	430 (380–490)	438 (385–495)
Incidence (includes HIV+TB)	290 (260–330)	292 (261–331)
Incidence (HIV+TB only)	0.31 (0.18–0.34)	0.32 (0.18–0.35)
Case detection, all forms (%)	80 (71–90)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2 (1.4–2.7)	21 (16–29)
MDR-TB cases among notified pulmonary TB cases	4 400 (3 100–6 000)	4 100 (3 000–5 500)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	97 353	4 669
Pulmonary, clinically diagnosed	123 510	0
Extrapulmonary	4 386	0

<b>Total new and relapse</b>	<b>229 918</b>
Previously treated, excluding relapses	14 474
<b>Total cases notified</b>	<b>244 392</b>

Among 97 221 new cases:

2 065 (2%) cases aged under 15 years; male:female ratio: 2.3

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	3 137 (3%)	13 419 (70%)	17 241
Laboratory-confirmed RR-/MDR-TB cases			3 962
Patients started on MDR-TB treatment			2 262

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	5 034	(2)
HIV-positive TB patients	26	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB	3 006	
HIV-positive people provided with IPT		

### Treatment success rate (%)

New cases registered in 2012	88
Previously treated cases registered in 2012	
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	41
XDR-TB cases started on second-line treatment in 2011	67

### Laboratories 2013

Smear (per 100 000 population)	2.6
Culture (per 5 million population)	0.9
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	16
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	117
% Funded domestically	27%
% Funded internationally	25%
% Unfunded	48%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **98 million**



# Russian Federation

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	17 (17–18)	12 (12–13)
Mortality (HIV+TB only)	1.4 (1–1.9)	0.98 (0.7–1.3)
Prevalence (includes HIV+TB)	160 (74–290)	114 (51–201)
Incidence (includes HIV+TB)	130 (120–140)	89 (82–100)
Incidence (HIV+TB only)	7.9 (6.9–9.1)	5.5 (4.8–6.4)
Case detection, all forms (%)	83 (74–91)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	19 (14–25)	49 (40–59)
MDR-TB cases among notified pulmonary TB cases	16 000 (11 000–20 000)	25 000 (20 000–30 000)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	37 779	7 866
Pulmonary, clinically diagnosed	43 859	7 194
Extrapulmonary	8 789	566

<b>Total new and relapse</b>	<b>106 053</b>
Previously treated, excluding relapses	36 480
<b>Total cases notified</b>	<b>142 533</b>

Among 90 427 new cases:

3 298 (4%) cases aged under 15 years; male:female ratio: 2.2

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	31 677 (84%)	12 066 (23%)	43 743
Laboratory-confirmed RR-/MDR-TB cases			13 521
Patients started on MDR-TB treatment			20 372

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status <sup>c</sup>	69 724	
HIV-positive TB patients	4 990	
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate (%)

New and relapse cases registered in 2012	69
Previously treated cases, excluding relapse, registered in 2012	37
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	37
XDR-TB cases started on second-line treatment in 2011	

## Laboratories 2013

Smear (per 100 000 population)	3.7
Culture (per 5 million population)	11.6
Drug susceptibility testing (per 5 million population)	7.6
Sites performing Xpert MTB/RIF	72
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014

National TB programme budget (US\$ millions)	1 827
% Funded domestically	100%
% Funded internationally	
% Unfunded	0%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> The reported number of TB patients with known HIV status is for new TB patients in the civilian sector only. It was not possible to calculate the percentage of all TB patients with known HIV status.

Population 2013 **143 million**



# South Africa

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	25 (15–38)	48 (28–73)
Mortality (HIV+TB only)	64 (47–83)	121 (90–158)
Prevalence (includes HIV+TB)	380 (210–590)	715 (396–1 126)
Incidence (includes HIV+TB)	450 (410–520)	860 (776–980)
Incidence (HIV+TB only)	270 (240–310)	520 (464–594)
Case detection, all forms (%)	69 (60–76)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.8 (1.4–2.3)	6.7 (5.4–8.2)
MDR-TB cases among notified pulmonary TB cases	4 600 (3 600–5 900)	2 200 (1 800–2 700)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	109 630	7 751
Pulmonary, clinically diagnosed	148 658	8 627
Extrapulmonary	37 709	5

**Total new and relapse** 312 380

Previously treated, excluding relapses 16 516

**Total cases notified** 328 896

Among 312 380 new and relapse cases:

36 671 (12%) cases aged under 15 years; male:female ratio: 1.2

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			258 401
Laboratory-confirmed RR-/MDR-TB cases			26 023
Patients started on MDR-TB treatment			10 663

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	294 504	(90)
HIV-positive TB patients	181 736	(62)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	146 973	(81)
HIV-positive TB patients on antiretroviral therapy (ART)	120 298	(66)
HIV-positive people screened for TB	961 967	
HIV-positive people provided with IPT	339 518	

## Treatment success rate (%)

New and relapse cases registered in 2012	77
Previously treated cases, excluding relapse, registered in 2012	64
HIV-positive TB cases, all types, registered in 2012	74
RR-/MDR-TB cases started on second-line treatment in 2011	45
XDR-TB cases started on second-line treatment in 2011	15

## Laboratories 2013

Smear (per 100 000 population)	0.4
Culture (per 5 million population)	1.4
Drug susceptibility testing (per 5 million population)	1.4
Sites performing Xpert MTB/RIF	207
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014







National TB programme budget (US\$ millions)	162
% Funded domestically	84%
% Funded internationally	16%
% Unfunded	0%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **53 million**



# Thailand

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	8.1 (4.9–12)	12 (7.3–18)
Mortality (HIV+TB only)	1.9 (1.3–2.4)	2.8 (2–3.6)
Prevalence (includes HIV+TB)	100 (48–170)	149 (72–252)
Incidence (includes HIV+TB)	80 (71–90)	119 (106–134)
Incidence (HIV+TB only)	12 (10–13)	17 (15–19)
Case detection, all forms (%)	80 (71–89)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	2 (1.4–2.8)	19 (14–25)
MDR-TB cases among notified pulmonary TB cases	1 000 (730–1 500)	880 (640–1 200)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	32 887	1 802
Pulmonary, clinically diagnosed	19 559	0
Extrapulmonary	9 293	0

<b>Total new and relapse</b>	<b>63 541</b>
Previously treated, excluding relapses	2 874
<b>Total cases notified</b>	<b>66 415</b>

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	3 246 (10%)	540 (12%)	3 866
Laboratory-confirmed RR-/MDR-TB cases			230
Patients started on MDR-TB treatment			230

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	54 991	(83)
HIV-positive TB patients	8 245	(15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	5 206	(63)
HIV-positive TB patients on antiretroviral therapy (ART)	4 890	(59)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	81
Previously treated cases, excluding relapse, registered in 2012	63
HIV-positive TB cases, all types, registered in 2012	70
RR-/MDR-TB cases started on second-line treatment in 2011	
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.6
Culture (per 5 million population)	4.8
Drug susceptibility testing (per 5 million population)	1.3
Sites performing Xpert MTB/RIF	14
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014

National TB programme budget (US\$ millions)	16 <sup>c</sup>
% Funded domestically	54%
% Funded internationally	33%
% Unfunded	13%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Data reported are only national level budgets for the Bureau of TB and the National Health Security Office, and do not include provincial, local and private sector budgets.

Population 2013 **67 million**



# Uganda

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	4.1 (2.2–6.6)	11 (5.8–18)
Mortality (HIV+TB only)	7.2 (5–9.9)	19 (13–26)
Prevalence (includes HIV+TB)	58 (32–91)	154 (85–243)
Incidence (includes HIV+TB)	62 (56–73)	166 (149–193)
Incidence (HIV+TB only)	32 (29–38)	86 (77–102)
Case detection, all forms (%)	73 (63–81)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.6–2.2)	12 (6.8–19)
MDR-TB cases among notified pulmonary TB cases	540 (230–840)	490 (270–780)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	25 442	1 312
Pulmonary, clinically diagnosed	12 852	615
Extrapulmonary	5 328	

<b>Total new and relapse</b>	<b>45 549</b>
Previously treated, excluding relapses	2 101
<b>Total cases notified</b>	<b>47 650</b>

Among 25 408 new cases:

649 (3%) cases aged under 15 years; male:female ratio: 1.9

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	92 (<1%)	397 (10%)	549
Laboratory-confirmed RR-/MDR-TB cases			117
Patients started on MDR-TB treatment			199

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	43 318	(91)
HIV-positive TB patients	20 648	(48)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	19 902	(96)
HIV-positive TB patients on antiretroviral therapy (ART)	13 399	(65)
HIV-positive people screened for TB	675 373	
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	77
Previously treated cases, excluding relapse, registered in 2012	66
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	77
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	3.5
Culture (per 5 million population)	0.5
Drug susceptibility testing (per 5 million population)	0.5
Sites performing Xpert MTB/RIF	37
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	39
% Funded domestically	5%
% Funded internationally	14%
% Unfunded	81%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **38 million**



# United Republic of Tanzania

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

## Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	6 (3.4–8.2)	12 (7–17)
Mortality (HIV+TB only)	6.1 (4.8–7.5)	12 (9.8–15)
Prevalence (includes HIV+TB)	85 (45–140)	172 (92–277)
Incidence (includes HIV+TB)	81 (77–84)	164 (157–170)
Incidence (HIV+TB only)	30 (29–31)	61 (58–63)
Case detection, all forms (%)	79 (77–83)	

## Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.1 (0.5–2)	3.1 (0.9–7.9)
MDR-TB cases among notified pulmonary TB cases	530 (240–960)	86 (25–220)

## TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	24 565	1 101
Pulmonary, clinically diagnosed	23 371	
Extrapulmonary	15 016	

**Total new and relapse** 64 053

Previously treated, excluding relapses 1 679

**Total cases notified** 65 732

Among 62 952 new cases:

6 658 (11%) cases aged under 15 years; male:female ratio: 1.4

## Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	1 192 (5%)	728 (26%)	2 020
Laboratory-confirmed RR-/MDR-TB cases			64
Patients started on MDR-TB treatment			28

## TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	54 504	(83)
HIV-positive TB patients	20 320	(37)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	19 835	(98)
HIV-positive TB patients on antiretroviral therapy (ART)	14 864	(73)
HIV-positive people screened for TB	457 901	
HIV-positive people provided with IPT	166	

## Treatment success rate (%)

New and relapse cases registered in 2012	90
Previously treated cases, excluding relapse, registered in 2012	80
HIV-positive TB cases, all types, registered in 2012	77
RR-/MDR-TB cases started on second-line treatment in 2011	75
XDR-TB cases started on second-line treatment in 2011	

## Laboratories 2013

Smear (per 100 000 population)	1.9
Culture (per 5 million population)	0.5
Drug susceptibility testing (per 5 million population)	0.1
Sites performing Xpert MTB/RIF	35
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2014







National TB programme budget (US\$ millions)	61
% Funded domestically	13%
% Funded internationally	17%
% Unfunded	69%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **49 million**



# Viet Nam

## HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	17 (12–24)	19 (13–26)
Mortality (HIV+TB only)	2 (1.2–2.9)	2.1 (1.3–3.2)
Prevalence (includes HIV+TB)	190 (79–350)	209 (86–384)
Incidence (includes HIV+TB)	130 (110–160)	144 (121–174)
Incidence (HIV+TB only)	9.4 (8–12)	10 (8.7–13)
Case detection, all forms (%)	76 (63–91)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	4 (2.5–5.4)	23 (17–30)
MDR-TB cases among notified pulmonary TB cases	3 000 (1 900–4 100)	2 100 (1 500–2 600)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	50 607	7 059
Pulmonary, clinically diagnosed	24 403	
Extrapulmonary	18 326	

<b>Total new and relapse</b>	<b>100 395</b>
Previously treated, excluding relapses	1 801
<b>Total cases notified</b>	<b>102 196</b>

Among 50 607 new cases:

143 (<1%) cases aged under 15 years; male:female ratio: 2.9

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	353 (<1%)	3 955 (45%)	4 531
Laboratory-confirmed RR-/MDR-TB cases			1 204
Patients started on MDR-TB treatment			948

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	71 374	(70)
HIV-positive TB patients	4 438	(6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	3 205	(72)
HIV-positive TB patients on antiretroviral therapy (ART)	2 715	(61)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

### Treatment success rate (%)

New and relapse cases registered in 2012	91
Previously treated cases, excluding relapse, registered in 2012	
HIV-positive TB cases, all types, registered in 2012	72
RR-/MDR-TB cases started on second-line treatment in 2011	72
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.1
Culture (per 5 million population)	1.3
Drug susceptibility testing (per 5 million population)	0.1
Sites performing Xpert MTB/RIF	27
Is second-line drug susceptibility testing available?	Yes, in country

### Financing TB control 2014







National TB programme budget (US\$ millions)	73
% Funded domestically	9%
% Funded internationally	18%
% Unfunded	73%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

## Population 2013 **92 million**





# Zimbabwe

## HIGH TB BURDEN | HIGH HIV BURDEN

### Estimates of TB burden<sup>a</sup> 2013

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	5.7 (3.6–7.4)	40 (25–52)
Mortality (HIV+TB only)	22 (17–27)	153 (121–189)
Prevalence (includes HIV+TB)	58 (33–89)	409 (235–630)
Incidence (includes HIV+TB)	78 (67–91)	552 (474–643)
Incidence (HIV+TB only)	56 (48–66)	395 (341–464)
Case detection, all forms (%)	42 (36–49)	

### Estimates of MDR-TB burden<sup>a</sup> 2013

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.9 (1–3.3)	8.3 (1.8–23)
MDR-TB cases among notified pulmonary TB cases	520 (270–900)	300 (66–820)

### TB case notifications 2013

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	11 404	1 275
Pulmonary, clinically diagnosed	15 807	
Extrapulmonary	4 413	

<b>Total new and relapse</b>	<b>32 899</b>
Previously treated, excluding relapses	2 379
<b>Total cases notified</b>	<b>35 278</b>

Among 32 899 new and relapse cases:

2 567 (8%) cases aged under 15 years; male:female ratio: 1.3

### Reported cases of RR-/MDR-TB 2013

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			4 276
Laboratory-confirmed RR-/MDR-TB cases			433
Patients started on MDR-TB treatment			351

### TB/HIV 2013

	NUMBER	(%)
TB patients with known HIV status	32 460	(92)
HIV-positive TB patients	22 442	(69)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	17 267	(77)
HIV-positive TB patients on antiretroviral therapy (ART)	17 267	(77)
HIV-positive people screened for TB	323 431	
HIV-positive people provided with IPT	10 926	

### Treatment success rate (%)

New cases registered in 2012	81
Previously treated cases registered in 2012	
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	81
XDR-TB cases started on second-line treatment in 2011	

### Laboratories 2013

Smear (per 100 000 population)	1.5
Culture (per 5 million population)	0.7
Drug susceptibility testing (per 5 million population)	0.7
Sites performing Xpert MTB/RIF	58
Is second-line drug susceptibility testing available?	Yes, in and outside country

### Financing TB control 2014

National TB programme budget (US\$ millions)	31
% Funded domestically	2%
% Funded internationally	43%
% Unfunded	55%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

Population 2013 **14 million**

